Output details

In Vitro Evaluation of Combined Temozolomide and Radiotherapy Using X-Rays and High-Linear Energy Transfer Radiation for Glioblastoma

2-year survival rate of patients with Glioblastoma is 6%. This paper looks at combining radiotherapy with the drug temozolomide which is capable of crossing the blood-brain barrier. Temozolomide is used clinically and improves 2-year survival rate to around 20% (for 45% of the population). In combination with ions, it may be possible to raise survival further, as higher doses of radiation can be delivered to the tumour. Clinical trials of the combined therapy are underway at the HIT facility in Germany. The PhD student (Barazzuol) was awarded the Mercier Prize from the Worshipful Company of Engineers for this research.